Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Global Orphan Drugs Market with Market Share, Growth, Trends Analysis by 2024-2032
The Orphan Drugs Market is projected to grow from USD 225.9 Billion in 2023 to USD 493.21 Billion by 2031, driven by rising prevalence of rare diseases, unmet medical needs, favorable regulatory policies, technological advancements, and growing public and patient advocacy. Key challenges include high R&D costs, limited patient populations, pricing and reimbursement issues, and lack of long-term data. Trends include focus on gene therapies, personalized medicine, stakeholder collaboration, and expansion into emerging markets. North America leads the market, followed by Europe and Asia Pacific.
Global Prostate Cancer Treatment Market Size - By Product
Prostate Cancer Treatment Market growth driven by rising incidence, awareness, and advances in technologies like immunotherapy and targeted biologics. Market expected to grow at 5.00% CAGR from 2024 to 2031, supported by healthcare infrastructure investments and personalized medicine.
Older adults should get their flu shots now. Here's why they also need stronger vaccines
Older adults should get the 2024–25 flu vaccine by early October. Specialized vaccines like Fluzone High-Dose, Fluad adjuvanted, and Flublok recombinant offer enhanced protection, with Medicare covering most. Side effects may be more common with high-dose shots.
Mpox global outbreak leads to significant increases in pharmaceutical stock markets
The WHO's mpox declaration led to significant stock market increases for pharmaceutical, medical tech, and biopharmaceutical companies, while airline stocks declined, reflecting investor concerns about mpox's global spread.
BioMarin Pharmaceutical Inc. (BMRN): Is This Biotech Stock A Good Buy?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is ranked 11th among the best biotech stocks to invest in according to hedge funds. The company focuses on treatments for rare diseases, with a robust product line and a strong internal pipeline. Despite challenges in patient diagnosis and commercialization costs, analysts are optimistic about its long-term profitability. The global biotech industry is expected to grow significantly, driven by innovation and demographic trends, with AI potentially revolutionizing drug discovery. BioMarin's Q2 2024 revenue rose 20% to $712 million, and the company raised its 2024 revenue forecast to between $2.75 billion and $2.825 billion.
Tolebrutinib Shows Promise in Non-Relapsing Secondary Progressive MS, Fenebrutinib ...
Sanofi's phase 3 HERCULES study of tolebrutinib met primary endpoint of reducing disability in non-relapsing secondary progressive multiple sclerosis (nrSPMS). Roche's fenebrutinib showed significant relapse suppression in relapsing MS without disability change. FDA accepted Axsome Therapeutics' resubmitted NDA for AXS-07 for acute migraine treatment.
Related Clinical Trials:
Asthma Biologics OK During Pregnancy if Patient Agrees, Consensus Statement Says
Biologic drugs for asthma can be used during conception, pregnancy, and breastfeeding with shared decision-making. Use should be recorded in registries, and restarting after birth is recommended if halted. Inactivated vaccinations for infants are safe even if mothers received biologics. Concerns remain due to limited clinical trial data, especially for newer biologics like tezepelumab.
Moderna, Takeda, and other Boston biotechs display work by disadvantaged artists
ArtLifting, founded by Liz and Spencer Powers, brokers art by disadvantaged artists, earning them $6.5 million. Their works, including by Allen Chamberland and Lisa Murphy, are displayed in corporate offices, including Moderna and Foundation Medicine, aiming to break stigmas and provide income.
FDA Approves Sparsentan, With Data Indicating Slowing of Kidney Function Decline in IgA
The FDA has fully approved sparsentan (Filspari; Travere Therapeutics), an oral, non-immunosuppressive medication that significantly slows kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN). The approval is based on the PROTECT study, which showed a 1.2 mL/min/1.73m²/year treatment effect over 2 years compared to irbesartan. Sparsentan is well-tolerated and offers a superior option for preserving kidney function.
Related Clinical Trials:
© Copyright 2025. All Rights Reserved by MedPath